Articles by Samantha Armstrong, MD
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on COSMIC-313, CheckMate 9ER, KEYMAKER-U03, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CheckMate 274, NIAGRA, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on TALAPRO-2, studies on oligometastatic disease, and more.
Drs. Samantha Armstrong and Karine Tawagi provide updated commentary on STAMPEDE, SunRISe-4, and SUNNIFORECAST trials.
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
The Two Onc Docs provide a brief overview of the the urothelial carcinoma, RCC, and prostate cancer presentations of note
Dr. Armstrong previews updates related to STAMPEDE, ARANOTE, LITESPARK-005, AMBASSADOR, and others.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.